The story of Sildenafil presents a complex case for stakeholders in the medicinal sector. While initially a tremendous success, producing billions, the intellectual property expiration and the subsequent flood of https://viagra909497.prublogger.com/40600171/the-little-copyright-and-pharma-a-risky-play